These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25686657)

  • 21. Preoperative 18F-fluorodeoxyglucose positron emission tomography can predict the tumor malignancy of small peripheral lung cancer.
    Kosaka T; Yamaki E; Tanaka S; Mogi A; Kuwano H
    Ann Thorac Cardiovasc Surg; 2014; 20(6):968-73. PubMed ID: 24284507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer.
    Shimizu K; Okita R; Saisho S; Yukawa T; Maeda A; Nojima Y; Nakata M
    Ann Nucl Med; 2015 Dec; 29(10):854-60. PubMed ID: 26254228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. F-18 FDG uptake on positron emission tomography as a predictor for lymphovascular invasion in patients with lung adenocarcinoma.
    Noda Y; Goshima S; Kanematsu M; Watanabe H; Kawada H; Kawai N; Ono H; Bae KT
    Ann Nucl Med; 2016 Jan; 30(1):11-7. PubMed ID: 26337532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pure ground glass nodular adenocarcinomas: Are preoperative positron emission tomography/computed tomography and brain magnetic resonance imaging useful or necessary?
    Cho H; Lee HY; Kim J; Kim HK; Choi JY; Um SW; Lee KS
    J Thorac Cardiovasc Surg; 2015 Sep; 150(3):514-20. PubMed ID: 26189165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Texture features of primary tumor on
    Aydos U; Ünal ER; Özçelik M; Akdemir D; Ekinci Ö; Taştepe Aİ; Memiş L; Atay LÖ; Akdemir ÜÖ
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(6):343-350. PubMed ID: 34752367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
    Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
    Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy.
    Ohno Y; Koyama H; Yoshikawa T; Matsumoto K; Aoyama N; Onishi Y; Sugimura K
    AJR Am J Roentgenol; 2012 Jan; 198(1):75-82. PubMed ID: 22194481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. N stage disease in patients with non-small cell lung cancer: efficacy of quantitative and qualitative assessment with STIR turbo spin-echo imaging, diffusion-weighted MR imaging, and fluorodeoxyglucose PET/CT.
    Ohno Y; Koyama H; Yoshikawa T; Nishio M; Aoyama N; Onishi Y; Takenaka D; Matsumoto S; Maniwa Y; Nishio W; Nishimura Y; Itoh T; Sugimura K
    Radiology; 2011 Nov; 261(2):605-15. PubMed ID: 21926377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of maximum standardized uptake value on fluorodeoxyglucose positron-emission tomography in predicting lymph node involvement in patients with primary non-small cell lung cancer.
    Muto J; Hida Y; Kaga K; Ohtaka K; Okamoto S; Tamaki N; Nakada-Kubota R; Hirano S; Matsui Y
    Anticancer Res; 2014 Feb; 34(2):805-10. PubMed ID: 24511016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of occult lymph node metastasis using volume-based PET parameters in small-sized peripheral non-small cell lung cancer.
    Park SY; Yoon JK; Park KJ; Lee SJ
    Cancer Imaging; 2015 Dec; 15():21. PubMed ID: 26694918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of the standardized uptake value in FDG-PET with the expression level of cell-cycle-related molecular biomarkers in resected non-small cell lung cancers.
    Nakamura H; Hirata T; Kitamura H; Nishikawa J
    Ann Thorac Cardiovasc Surg; 2009 Oct; 15(5):304-10. PubMed ID: 19901884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy.
    Takenaka D; Ohno Y; Matsumoto K; Aoyama N; Onishi Y; Koyama H; Nogami M; Yoshikawa T; Matsumoto S; Sugimura K
    J Magn Reson Imaging; 2009 Aug; 30(2):298-308. PubMed ID: 19629984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up?
    Chen W; Jian W; Li HT; Li C; Zhang YK; Xie B; Zhou DQ; Dai YM; Lin Y; Lu M; Huang XQ; Xu CX; Chen L
    Magn Reson Imaging; 2010 Jun; 28(5):613-20. PubMed ID: 20418042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mediastinal lymph nodes staging by 18F-FDG PET/CT for early stage non-small cell lung cancer: a multicenter study.
    Li X; Zhang H; Xing L; Ma H; Xie P; Zhang L; Xu X; Yue J; Sun X; Hu X; Chen M; Xu W; Chen L; Yu J
    Radiother Oncol; 2012 Feb; 102(2):246-50. PubMed ID: 22100657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hybrid [¹⁸F]-FDG PET/MRI including non-Gaussian diffusion-weighted imaging (DWI): preliminary results in non-small cell lung cancer (NSCLC).
    Heusch P; Köhler J; Wittsack HJ; Heusner TA; Buchbender C; Poeppel TD; Nensa F; Wetter A; Gauler T; Hartung V; Lanzman RS
    Eur J Radiol; 2013 Nov; 82(11):2055-60. PubMed ID: 23830904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential expression and prognostic significance of GLUT1 according to histologic type of non-small-cell lung cancer and its association with volume-dependent parameters.
    Koh YW; Lee SJ; Park SY
    Lung Cancer; 2017 Feb; 104():31-37. PubMed ID: 28212997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index.
    Vesselle H; Salskov A; Turcotte E; Wiens L; Schmidt R; Jordan CD; Vallières E; Wood DE
    J Thorac Oncol; 2008 Sep; 3(9):971-8. PubMed ID: 18758298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.